Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Sotio Biotech Inc.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Stanford University
Erasca, Inc.
Jonsson Comprehensive Cancer Center
Degron Therapeutics Co.
Actym Therapeutics, Inc.
Ikena Oncology
Columbia University
Thomas Jefferson University
Theratechnologies
National Cancer Institute (NCI)
ABM Therapeutics Corporation
National Cancer Institute (NCI)
MacroGenics
Fore Biotherapeutics
Celgene
Celgene
University of Chicago
Calando Pharmaceuticals
Rutgers, The State University of New Jersey
Mannkind Corporation